U.S. Compounding Pharmacies Market Size & Growth Report

U.S. Compounding Pharmacies Market - Industry Outlook & Forecast 2024-2029

244 pages

41 tables

80 charts

1 region

1 countries

28 company

6 segments

Purchase Options

$4200.00
$4999.00
$5999.00
$2000.00

Have a question?

Please get in touch with our team in case of any queries

+1-312-235-2040

THE U.S. COMPOUNDING PHARMACIES MARKET SIZE IS EXPECTED TO REACH USD 6.21 BILLION BY 2029 FROM USD 4.89 BILLION IN 2023, GROWING AT A CAGR OF 4.06% DURING THE FORECAST PERIOD.

The U.S. Compounding Pharmacies Market Size, Share, & Trends Analysis Report By

  1. Product Type: Oral, Topical, Parenteral, Ophthalmic, and Others
  2. Pharmacy Type: 503A and 503B
  3. Sterility Type: Sterile and Non-sterile
  4. Compounding Type: Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), and Pharmaceutical Dosage Alteration (PDA)
  5. Application: Pain Management, Hormone Replacement Therapy, Anti-aging & Skin Care, Nutritional Supplements, and Others
  6. Age Cohort: Adult, Geriatric, and Pediatric

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

Customize this Report

This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize

U.S. COMPOUNDING PHARMACIES MARKET REPORT SCOPE

REPORT ATTRIBUTEDETAILS
Market Size (2029)USD 6.21 Billion
Market Size (2023)USD 4.89 Billion
CAGR (2023-2029)4.06%
HISTORIC YEAR2020-2022
BASE YEAR2023
FORECAST YEAR2024-2029
SEGMENTS BYProduct Type, Pharmacy Type, Sterility Type, Compounding Type, Application, Age Cohort
KEY PLAYERSAvella Specialty Pharmacy, CAPS, Fagron, Fresenius Kabi, and PenCol Pharmacy
Interested in this Report?

Download a Sample!

INDUSTRY OUTLOOK

The U.S. compounding pharmacies market size was valued at USD 4.89 billion in 2023 and is expected to reach USD 6.21 billion by 2029, growing at a CAGR of 4.06% during the forecast period. The demand for customized drug formulations grows as healthcare increasingly moves towards personalized medicine. The market provides a solution for patients who require specific dosages, alternative delivery methods, or medications free from certain allergens or additives. Compounded medications can address gaps left by commercial drug manufacturers, such as discontinued drugs or those unavailable in specific strengths or forms. This capability is crucial for patients who rely on medications that are otherwise unavailable.

The U.S. compounding pharmacies market occupies a unique niche within the broader healthcare landscape, providing customized medications that cater to the specific needs of individual patients. Unlike conventional pharmaceuticals, which are produced in bulk by large pharmaceutical companies, licensed pharmacists prepare compounded drugs according to specific prescriptions. This market segment plays a vital role in offering personalized treatment solutions, addressing gaps in conventional drug availability, and meeting the needs of patients requiring unique formulations.

A complex interplay between federal and state authorities characterizes the regulatory framework for compounding pharmacies in the US. Historically, compounding practices were subject to oversight primarily by state boards of pharmacy. However, high-profile cases of contamination and quality issues have prompted increased federal scrutiny. The Drug Quality and Security Act (DQSA) of 2013 introduced new regulations, particularly focusing on "outsourcing facilities" that compound drugs in bulk for interstate distribution. This act aims to enhance the safety and quality of compounded drugs by imposing stricter guidelines and registration requirements. Furthermore, the U.S. compounding pharmacies market plays a crucial role in providing personalized medication solutions and addressing specific patient needs that are not met by standard pharmaceutical products. Driven by factors such as the demand for personalized medicine, an aging population, and technological advancements, the market continues to evolve.

MARKET TRENDS & DRIVERS

Advanced Technology Integration

Integrating advanced technologies such as automation, robotic systems, and digital platforms creates new opportunities for the U.S. compounding pharmacies market. These innovations improve operational efficiency, enhance patient care, ensure compliance, and pave the way for future advancements in personalized medicine. As pharmacies continue to adopt these technologies, they will be better equipped to meet the evolving demands of healthcare and provide tailored medication solutions to patients. Also, adopting artificial intelligence (AI) and machine learning (ML) holds great potential for predictive analytics in compounding, such as anticipating patient needs and personalizing formulations based on genetic profiles.

Growing Demand for Compounded Bioidentical Menopausal Hormone Therapy (BMHT) Among Women

The growing demand for compounded bio-identical menopausal hormone therapy is reshaping the U.S. compounding pharmacies market, providing new opportunities for growth and innovation. As women increasingly seek personalized, natural solutions for managing menopausal symptoms, compounding pharmacies are well-positioned to meet this demand. By offering customized hormone treatments that prioritize patient safety and wellness, compounding pharmacies can capitalize on the expanding market for BMHT while contributing to the broader trend of personalized healthcare in the US.

Growing Geriatric Population & Acceptance of Personalized Medications

The growing geriatric population and the increasing acceptance of personalized medications are key drivers of the U.S. compounding pharmacies market. Compounding pharmacies are uniquely positioned to meet the complex and individualized needs of elderly patients, providing customized solutions that enhance healthcare outcomes. As demand for tailored medications grows, compounding pharmacies will continue to play a vital role in the U.S. healthcare system, providing personalized care for diverse patients.

Growing Significance of Compounding for Drug Adherence

The growing significance of compounding for drug adherence is a key driver of the U.S. compounding pharmacies market. Compounding pharmacies play a vital role in improving medication compliance and, ultimately, patient outcomes by offering customized solutions that address the specific needs of diverse patient populations. With advancements in technology and a growing focus on personalized medicine, the future of the compounding pharmacies market is poised for continued growth and innovation.

Rapid Identification of Chronic Diseases

The increasing prevalence of chronic diseases and the advancements in their rapid identification are reshaping the U.S. compounding pharmacies market. Compounding pharmacies offer customized treatment options that address the specific needs of patients with chronic conditions, improving medication adherence, patient outcomes, and overall quality of care. As the demand for personalized medicine continues to grow, compounding pharmacies will remain at the forefront of providing innovative and tailored solutions for chronic disease management, driving their expansion and influence within the healthcare sector.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT TYPE

The U.S. compounding pharmacies market by product type is segmented into oral, topical, parenteral, ophthalmic, and others. The oral segment holds the most significant U.S. market share. The oral compounds segment can be tailored to patients with allergies to certain excipients or those who require specific dosages that are not commercially available. Customized oral medications are particularly beneficial for pediatric and geriatric patients needing adjusted dosages or specific formulations to improve adherence. Compounding pharmacies can add flavorings to oral medications to make them more palatable for children or patients with difficulty swallowing pills. The demand for oral compounds is driven by the need for personalized dosing, especially in conditions like hormone replacement therapy (HRT) and pain management. Furthermore, parenteral compounds are often used for patients needing customized dosages or drug combinations unavailable in commercial products. Many compounded parenteral medications are utilized in hospital settings for specialized treatments, such as chemotherapy or pain management, where individualized care is crucial.

INSIGHTS BY PHARMACY TYPE

The 503A pharmacy type held the most significant share of the U.S. compounding pharmacies market and is projected to witness the highest segmental CAGR of 4.30% during the forecast period. 503A pharmacies are traditional compounding pharmacies that primarily focus on preparing medications for individual patients based on a prescription from a licensed healthcare provider. They often serve local communities and focus on providing customized solutions for conditions such as hormone replacement therapy, pediatric needs, and dermatological treatments. State boards of pharmacy primarily regulate 503A pharmacies and must adhere to state-specific compounding regulations. The FDA's oversight is more limited compared to 503B facilities. Furthermore, the 503B pharmacies, also known as outsourcing facilities, are designed to compound medications on a larger scale, primarily for healthcare institutions such as hospitals, clinics, and long-term care facilities. 503

INSIGHTS BY STERILITY TYPE

The U.S. compounding pharmacies market by sterility type is segmented into sterile and non-sterile. The sterile segment holds the largest segmental market share. The demand for sterile compounding is driven by its applications in hospitals and clinical settings, where compounded sterile preparations (CSPs) are used for various treatments. These include intravenous (IV) medications, chemotherapy agents, and other critical therapies. The growth of personalized medicine and an increasing number of patients requiring complex treatments contribute to the rising demand for sterile compounding services. Furthermore, the demand for non-sterile compounding is significant due to its broad range of applications. This includes customized formulations for hormone replacement therapy, pediatric medications, and dermatological treatments.

INSIGHTS BY COMPOUNDING TYPE

The U.S. compounding pharmacies market by compounding type is segmented into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA). The pharmaceutical ingredient alteration (PIA) segment dominated the U.S. market share, accounting for over 39% of the revenue in 2023. PIA involves modifying the ingredients of a medication to meet the specific needs of individual patients better. PIA allows for significant customization, addressing patients requiring non-standard dosages or formulations due to unique health conditions, allergies, or other requirements. The demand for PIA is driven by patients needing tailored solutions for conditions that standard pharmaceutical formulations cannot adequately address. This includes pediatric patients who may need medications in different dosages or forms. Furthermore, the CUPM segment is critical in filling gaps caused by drug shortages or discontinuations. This ensures patients can continue receiving necessary treatments even when standard options are unavailable. CUPM is particularly important for patients requiring niche or rare medications that mainstream pharmaceutical manufacturers do not produce. This can include specialized cancer treatments or rare disease medications.

INSIGHTS BY APPLICATION

The U.S. compounding pharmacies market by application is segmented into pain management, hormone replacement therapy, anti-aging & skin care, nutritional supplements, and others. The pain management segment holds the most substantial market share. Compounding pharmacies play a crucial role in pain management by offering customized medications tailored to patients' needs. For chronic pain sufferers, commercially available pain relief drugs may not be effective or may cause adverse side effects. Compounded pain medications allow for personalized dosages, alternative delivery methods (like topical creams, gels, or transdermal patches), and combinations of multiple drugs to maximize relief while minimizing side effects. The increasing opioid crisis has also spurred the demand for non-opioid, compounded alternatives to manage chronic pain, positioning compounding pharmacies as critical in pain management solutions. Furthermore, hormone replacement therapy (HRT) is one of the most sought-after services in the U.S. compounding pharmacies market. Many patients undergoing HRT for conditions like menopause, thyroid disorders, or low testosterone levels seek bioidentical hormones, which are chemically identical to the hormones naturally produced by the body. Compounding pharmacies offer customized formulations of bioidentical hormones in various forms—creams, gels, pills, or injections—adjusting dosages to meet individual needs. This market has experienced substantial growth due to the aging population and increased awareness of personalized medicine options for hormonal imbalances.

INSIGHTS BY AGE COHORT

The adult age cohort segment dominates the U.S. compounding pharmacies market share. Many adults seek personalized treatments for conditions requiring precise dosage adjustments or specific formulations unavailable through commercial medications. Common treatments include hormone replacement therapy (HRT) for both men and women, pain management, and dermatological compounds for skin conditions. Adults also benefit from compounded medications to avoid allergens or intolerances in standard pharmaceuticals and medications tailored to specific lifestyle needs. Furthermore, the pediatric population is a key demographic for the United States compounding pharmacies market, as children often require customized medications unavailable in standard dosages or formulations. Compounded medications are essential for:

  1. Adjusting the strength of medications to suit a child's weight or age
  2. Creating alternative dosage forms, such as flavored liquids, chewable tablets, or topical gels, to make administration easier for young children
  3. Removing allergens or non-essential ingredients that could cause adverse reactions in children

Pediatric patients frequently require compounded medications for conditions such as asthma, allergies, dermatological issues, and rare diseases, where commercially available drugs may not be appropriate or palatable. The ability to offer personalized, child-friendly medications enhances treatment adherence and improves overall patient outcomes in this age group.

COMPETITIVE LANDSCAPE

The U.S. compounding pharmacies market operates in a dynamic and evolving landscape characterized by diverse players, regulatory challenges, and increasing demand for personalized medications. As healthcare trends shift towards personalized treatment solutions, the competition in this sector has intensified. Compounding pharmacies, which offer customized medications tailored to individual patient needs, compete with large pharmaceutical manufacturers, retail pharmacies, and specialized compounding firms. This competition is shaped by factors such as regulatory compliance, quality assurance, technological advancements, and market differentiation. Furthermore, technology plays an increasingly important role in the US compounding pharmacies market. Pharmacies that invest in automation, digital platforms, and advanced compounding equipment have a competitive advantage. Automated compounding machines, for example, can enhance accuracy, reduce human error, and increase production efficiency, especially in sterile environments where precision is critical.

The key players in the U.S. compounding pharmacies market are Avella Specialty Pharmacy, CAPS, Fagron, Fresenius Kabi, and PenCol Pharmacy. Avella Specialty Pharmacy, a prominent player in the market, is known for its focus on providing personalized, high-quality compounded medications. Avella specializes in sterile and non-sterile compounding, offering a wide range of personalized medications, including hormone replacement therapies, pain management solutions, and dermatological preparations. Also, Avella invests in advanced compounding technologies and quality assurance practices to ensure the safety and efficacy of its products.

SNAPSHOT

The U.S. compounding pharmacies market size is expected to grow at a CAGR of approximately 4.06% from 2023 to 2029.

The following factors are likely to contribute to the growth of the U.S. compounding pharmacies market during the forecast period:

  1. Growing Geriatric Population & Acceptance of Personalized Medications
  2. Growing Significance of Compounding for Drug Adherence
  3. Increasing Drug Shortage
  4. Rapid Identification of Chronic Diseases

Base Year: 2023

Forecast Year: 2024-2029

The report considers the present scenario of the U.S. compounding pharmacies market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Company Profiles

  1. Avella Specialty Pharmacy
  2. Business Overview
  3. Product Offerings
  4. Key Strategies
  5. Key Strengths
  6. Key Opportunities
  7. CAPS
  8. Fagron
  9. Fresenius Kabi
  10. PenCol Pharmacy

Other Prominent Vendors

  1. Austin Compounding Pharmacy
  2. Business Overview
  3. Product Offerings
  4. Capstone Compounding Pharmacy
  5. Charles River Laboratories
  6. Dougherty's Pharmacy
  7. Eastern States Compounding Pharmacy
  8. Everwell Specialty Pharmacy
  9. Harrow
  10. Hill’s Compounding Pharmacy and Milford Pharmacy
  11. INNOVATIVE RX
  12. Institutional Pharmacy Solutions
  13. ITC Compounding Pharmacy
  14. McGuff Company
  15. MediVera Compounding Pharmacy
  16. Nephron Pharmaceuticals
  17. PCCA
  18. Precision Compounding Pharmacy
  19. QuVa Pharma
  20. Sixth Avenue Medical Pharmacy
  21. St. Anthony Pharmacy
  22. The Compounding Pharmacy of America
  23. Triangle Compounding
  24. Valor Compounding Pharmacy
  25. Vertisis Custom Pharmacy

Segmentation by Product Type

  1. Oral
  2. Topical
  3. Parenteral
  4. Ophthalmic
  5. Others

Segmentation by Pharmacy Type

  1. 503A
  2. 503B

Segmentation by Sterility Type

  1. Sterile
  2. Non-sterile

Segmentation by Compounding Type

  1. Pharmaceutical Ingredient Alteration (PIA)
  2. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
  3. Pharmaceutical Dosage Alteration (PDA)

Segmentation by Application

  1. Pain Management
  2. Hormone Replacement Therapy
  3. Anti-aging & Skin Care
  4. Nutritional Supplements
  5. Others

Segmentation by Age Cohort

  1. Adult
  2. Geriatric
  3. Pediatric

Frequently Asked Questions

How big is the U.S. compounding pharmacies market?

The U.S. compounding pharmacies market size was valued at USD 4.89 billion in 2023 and is expected to reach USD 6.21 billion by 2029.

What is the growth rate of the U.S. compounding pharmacies market?

The U.S. compounding pharmacies market is expected to grow at a CAGR of 4.06% from 2023 to 2029.

What are the significant trends in the U.S. compounding pharmacies market?

Advanced technology integration, growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women, and growing collaboration between compounding pharmacies & healthcare providers are significant trends in the U.S. compounding pharmacies industry.

Which compounding type segment dominates the U.S. compounding pharmacies market share?

The pharmaceutical ingredient alteration (PIA) compounding type held the largest U.S. compounding pharmacies market share, accounting for over 39% in 2023.

Who are the key players in the U.S. compounding pharmacies market?

Avella Specialty Pharmacy, CAPS, Fagron, Fresenius Kabi, and PenCol Pharmacy are the key players in the U.S. compounding pharmacies market.

EXHIBIT 1 MARKET SIZE CALCULATION APPROACH 2023

EXHIBIT 2 US COMPOUNDING PHARMACY MARKET BY PRODUCT TYPE: MARKET SHARE 2023 & 2029

EXHIBIT 3 US COMPOUNDING PHARMACY MARKET BY PHARMACY TYPE: MARKET SHARE 2023 & 2029

EXHIBIT 4 US COMPOUNDING PHARMACY MARKET BY STERILITY TYPE: MARKET SHARE 2023 & 2029

EXHIBIT 5 US COMPOUNDING PHARMACY MARKET BY COMPOUNDING TYPE: MARKET SHARE 2023 & 2029

EXHIBIT 6 US COMPOUNDING PHARMACY MARKET BY APPLICATION: MARKET SHARE 2023 & 2029

EXHIBIT 7 US COMPOUNDING PHARMACY MARKET BY AGE COHORT: MARKET SHARE 2023 & 2029

EXHIBIT 8 IMPACT OF ADVANCED TECHNOLOGY INTEGRATION

EXHIBIT 9 IMPACT OF GROWTH IN DEMAND FOR COMPOUNDED BIOIDENTICAL MENOPAUSAL HORMONE THERAPY (BMHT) AMONG WOMEN

EXHIBIT 10 IMPACT OF GROWTH IN COLLABORATION BETWEEN COMPOUNDING PHARMACIES & HEALTHCARE PROVIDERS

EXHIBIT 11 IMPACT OF GROWTH IN GERIATRIC POPULATION & ACCEPTANCE OF PERSONALIZED MEDICATIONS

EXHIBIT 12 IMPACT OF GROWTH IN SIGNIFICANCE OF COMPOUNDING FOR DRUG ADHERENCE

EXHIBIT 13 IMPACT OF INCREASE IN DRUG SHORTAGE IN US

EXHIBIT 14 IMPACT OF RAPID IDENTIFICATION OF CHRONIC DISEASES

EXHIBIT 15 IMPACT OF ISSUES RELATED TO SAFETY STANDARDS OF COMPOUNDED DRUGS

EXHIBIT 16 IMPACT OF CHANGES IN REGULATORY CONSTRAINTS

EXHIBIT 17 IMPACT OF POOR COMPOUNDING PRACTICES RESULTS IN QUALITY PROBLEMS

EXHIBIT 18 US COMPOUNDING PHARMACY MARKET 2020–2029 ($ BILLION)

EXHIBIT 19 FIVE FORCES ANALYSIS 2023

EXHIBIT 20 INCREMENTAL GROWTH BY PRODUCT TYPE 2023 & 2029

EXHIBIT 21 US COMPOUNDING PHARMACY MARKET BY PRODUCT TYPE 2023-2029: INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 22 US COMPOUNDING PHARMACY MARKET BY PRODUCT TYPE 2023-2029: ABSOLUTE GROWTH (%)

EXHIBIT 23 US ORAL COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 24 US ORAL COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 25 US TOPICAL COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 26 US TOPICAL COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 27 US PARENTERAL COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 28 US PARENTERAL COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 29 US OPHTHALMIC COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 30 US OPHTHALMIC COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 31 US OTHERS COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 32 US OTHERS COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 33 INCREMENTAL GROWTH BY PHARMACY TYPE 2023 & 2029

EXHIBIT 34 US COMPOUNDING PHARMACY MARKET BY PHARMACY TYPE 2023-2029: INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 35 US COMPOUNDING PHARMACY MARKET BY PHARMACY TYPE 2023-2029: ABSOLUTE GROWTH (%)

EXHIBIT 36 US 503A COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 37 US 503A COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 38 US 503B COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 39 US 503B COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 40 INCREMENTAL GROWTH BY STERILITY TYPE 2023 & 2029

EXHIBIT 41 US COMPOUNDING PHARMACY MARKET BY STERILITY TYPE 2023-2029: INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 42 US COMPOUNDING PHARMACY MARKET BY STERILITY TYPE 2023-2029: ABSOLUTE GROWTH (%)

EXHIBIT 43 US STERILE COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 44 US STERILE COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 45 US NON-STERILE COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 46 US NON-STERILE COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 47 INCREMENTAL GROWTH BY COMPOUNDING TYPE 2023 & 2029

EXHIBIT 48 US COMPOUNDING PHARMACY MARKET BY COMPOUNDING TYPE 2023-2029: INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 49 US COMPOUNDING PHARMACY MARKET BY COMPOUNDING TYPE 2023-2029: ABSOLUTE GROWTH (%)

EXHIBIT 50 US PHARMACEUTICAL INGREDIENT ALTERATION (PIA) COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 51 US PHARMACEUTICAL INGREDIENT ALTERATION (PIA) COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 52 US CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM) COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 53 US CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM) COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 54 US PHARMACEUTICAL DOSAGE ALTERATION (PDA) COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 55 US PHARMACEUTICAL DOSAGE ALTERATION (PDA) COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 56 INCREMENTAL GROWTH BY APPLICATION 2023 & 2029

EXHIBIT 57 US COMPOUNDING PHARMACY MARKET BY APPLICATION 2023-2029: INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 58 US COMPOUNDING PHARMACY MARKET BY APPLICATION 2023-2029: ABSOLUTE GROWTH (%)

EXHIBIT 59 US PAIN MANAGEMENT COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 60 US PAIN MANAGEMENT COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 61 US HORMONE REPLACEMENT THERAPY COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 62 US HORMONE REPLACEMENT THERAPY COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 63 US ANTI-AGING & SKIN CARE COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 64 US ANTI-AGING & SKIN CARE COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 65 US NUTRITIONAL SUPPLEMENTS COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 66 US NUTRITIONAL SUPPLEMENTS COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 67 US OTHERS COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 68 US OTHERS COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 69 INCREMENTAL GROWTH BY AGE COHORT 2023 & 2029

EXHIBIT 70 US COMPOUNDING PHARMACY MARKET BY AGE COHORT 2023-2029: INCREMENTAL GROWTH ($ BILLION)

EXHIBIT 71 US COMPOUNDING PHARMACY MARKET BY AGE COHORT 2023-2029: ABSOLUTE GROWTH (%)

EXHIBIT 72 US ADULT COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 73 US ADULT COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 74 US GERIATRIC COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 75 US GERIATRIC COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 76 US PEDIATRIC COMPOUNDING PHARMACY MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 77 US PEDIATRIC COMPOUNDING PHARMACY MARKET 2020-2029 ($ BILLION)

EXHIBIT 78 VENDORS OFFERING COMPOUNDING PHARMACY PRODUCTS: MARKET DOMINANCE ANALYSIS

EXHIBIT 79 VENDORS OFFERING COMMERCIAL COMPOUNDING PHARMACY PRODUCTS: CAPABILITIES & EXPERTISE ASSESSMENT

EXHIBIT 80 KEY CAVEATS


LIST OF TABLES


TABLE 1 AVELLA SPECIALTY PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 2 CAPS: MAJOR PRODUCT OFFERINGS

TABLE 3 FAGRON: MAJOR PRODUCT OFFERINGS

TABLE 4 FRESENIUS KABI: MAJOR PRODUCT OFFERINGS

TABLE 5 PENCOL PHARMACY.: MAJOR PRODUCT OFFERINGS

TABLE 6 AUSTIN COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 7 CAPSTONE COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 8 CHARLES RIVER LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 9 DOUGHERTY'S PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 10 EASTERN STATES COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 11 EVERWELL SPECIALTY PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 12 HARROW: MAJOR PRODUCT OFFERINGS

TABLE 13 HILL’S COMPOUNDING PHARMACY AND MILFORD PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 14 INNOVATIVE RX: MAJOR PRODUCT OFFERINGS

TABLE 15 INSTITUTIONAL PHARMACY SOLUTIONS: MAJOR PRODUCT OFFERINGS

TABLE 16 ITC COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 17 MCGUFF COMPANY: MAJOR PRODUCT OFFERINGS

TABLE 18 MEDIVERA COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 19 NEPHRON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS

TABLE 20 PCCA: MAJOR PRODUCT OFFERINGS

TABLE 21 PRECISION COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 22 QUVA PHARMA: MAJOR PRODUCT OFFERINGS

TABLE 23 SIXTH AVENUE MEDICAL PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 24 ST. ANTHONY PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 25 THE COMPOUNDING PHARMACY OF AMERICA: MAJOR PRODUCT OFFERINGS

TABLE 26 TRIANGLE COMPOUNDING: MAJOR PRODUCT OFFERINGS

TABLE 27 VALOR COMPOUNDING PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 28 VERTISIS CUSTOM PHARMACY: MAJOR PRODUCT OFFERINGS

TABLE 29 US COMPOUNDING PHARMACY MARKET BY PRODUCT TYPE 2023−2029 ($ BILLION)

TABLE 30 US COMPOUNDING PHARMACY MARKET BY PRODUCT TYPE 2023−2029 (%)

TABLE 31 US COMPOUNDING PHARMACY MARKET BY PHARMACY TYPE 2023−2029 ($ BILLION)

TABLE 32 US COMPOUNDING PHARMACY MARKET BY PHARMACY TYPE 2023−2029 (%)

TABLE 33 US COMPOUNDING PHARMACY MARKET BY STERILITY TYPE 2023−2029 ($ BILLION)

TABLE 34 US COMPOUNDING PHARMACY MARKET BY STERILITY TYPE 2023−2029 (%)

TABLE 35 US COMPOUNDING PHARMACY MARKET BY COMPOUNDING TYPE 2023−2029 ($ BILLION)

TABLE 36 US COMPOUNDING PHARMACY MARKET BY COMPOUNDING TYPE 2023−2029 (%)

TABLE 37 US COMPOUNDING PHARMACY MARKET BY APPLICATION 2023−2029 ($ BILLION)

TABLE 38 US COMPOUNDING PHARMACY MARKET BY APPLICATION 2023−2029 (%)

TABLE 39 US COMPOUNDING PHARMACY MARKET BY AGE COHORT 2023−2029 ($ BILLION)

TABLE 40 US COMPOUNDING PHARMACY MARKET BY AGE COHORT 2023−2029 (%)

TABLE 41 CURRENCY CONVERSION 2016–2023

1. SCOPE & COVERAGE

1.1. MARKET DEFINITION

1.1.1. INCLUSIONS

1.1.2. EXCLUSIONS

1.1.3. MARKET ESTIMATION CAVEATS

1.2. SEGMENTS COVERED & DEFINITION

1.2.1. MARKET SEGMENTATION BY PRODUCT TYPE

1.2.2. MARKET SEGMENTATION BY PHARMACY TYPE

1.2.3. MARKET SEGMENTATION BY STERILITY TYPE

1.2.4. MARKET SEGMENTATION BY COMPOUNDING TYPE

1.2.5. MARKET SEGMENTATION BY APPLICATION

1.2.6. MARKET SEGMENTATION BY AGE COHORT

1.2.7. REGIONS & COUNTRIES COVERED

1.3. MARKET DERIVATION

1.3.1. HISTORIC, BASE, & FORECAST YEARS

2. PREMIUM INSIGHTS

2.1. OPPORTUNITY POCKETS

2.2. OVERVIEW

3. MARKET AT A GLANCE

4. INTRODUCTION

4.1. OVERVIEW

5. MARKET OPPORTUNITIES & TRENDS

5.1. ADVANCED TECHNOLOGY INTEGRATION

5.2. GROWTH IN DEMAND FOR COMPOUNDED BIOIDENTICAL MENOPAUSAL HORMONE THERAPY (BMHT) AMONG WOMEN

5.3. GROWTH IN COLLABORATION BETWEEN COMPOUNDING PHARMACIES & HEALTHCARE PROVIDERS

6. MARKET GROWTH ENABLERS

6.1. GROWTH IN GERIATRIC POPULATION & ACCEPTANCE OF PERSONALIZED MEDICATIONS

6.2. GROWTH IN SIGNIFICANCE OF COMPOUNDING FOR DRUG ADHERENCE

6.3. INCREASE IN DRUG SHORTAGE IN US

6.4. RAPID IDENTIFICATION OF CHRONIC DISEASES

7. MARKET RESTRAINTS

7.1. ISSUES RELATED TO SAFETY STANDARDS OF COMPOUNDED DRUGS

7.2. CHANGES IN REGULATORY CONSTRAINTS

7.3. POOR COMPOUNDING PRACTICES RESULTS IN QUALITY PROBLEMS

8. MARKET LANDSCAPE

8.1. MARKET OVERVIEW

8.2. MARKET SIZE & FORECAST

8.3. FIVE FORCES ANALYSIS

8.3.1. THREAT OF NEW ENTRANTS

8.3.2. BARGAINING POWER OF SUPPLIERS

8.3.3. BARGAINING POWER OF BUYERS

8.3.4. THREAT OF SUBSTITUTES

8.3.5. COMPETITIVE RIVALRY

9. PRODUCT TYPE

9.1. MARKET SNAPSHOT & GROWTH ENGINE

9.2. MARKET OVERVIEW

9.3. ORAL

9.3.1. MARKET OVERVIEW

9.3.2. MARKET SIZE & FORECAST

9.4. TOPICAL

9.4.1. MARKET OVERVIEW

9.4.2. MARKET SIZE & FORECAST

9.5. PARENTERAL

9.5.1. MARKET OVERVIEW

9.5.2. MARKET SIZE & FORECAST

9.6. OPHTHALMIC

9.6.1. MARKET OVERVIEW

9.6.2. MARKET SIZE & FORECAST

9.7. OTHERS

9.7.1. MARKET OVERVIEW

9.7.2. MARKET SIZE & FORECAST

10. PHARMACY TYPE

10.1. MARKET SNAPSHOT & GROWTH ENGINE

10.2. MARKET OVERVIEW

10.3. 503A

10.3.1. MARKET OVERVIEW

10.3.2. MARKET SIZE & FORECAST

10.4. 503B

10.4.1. MARKET OVERVIEW

10.4.2. MARKET SIZE & FORECAST

11. STERILITY TYPE

11.1. MARKET SNAPSHOT & GROWTH ENGINE

11.2. MARKET OVERVIEW

11.3. STERILE

11.3.1. MARKET OVERVIEW

11.3.2. MARKET SIZE & FORECAST

11.4. NON-STERILE

11.4.1. MARKET OVERVIEW

11.4.2. MARKET SIZE & FORECAST

12. COMPOUNDING TYPE

12.1. MARKET SNAPSHOT & GROWTH ENGINE

12.2. MARKET OVERVIEW

12.3. PHARMACEUTICAL INGREDIENT ALTERATION (PIA)

12.3.1. MARKET OVERVIEW

12.3.2. MARKET SIZE & FORECAST

12.4. CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM)

12.4.1. MARKET OVERVIEW

12.4.2. MARKET SIZE & FORECAST

12.5. PHARMACEUTICAL DOSAGE ALTERATION (PDA)

12.5.1. MARKET OVERVIEW

12.5.2. MARKET SIZE & FORECAST

13. APPLICATION

13.1. MARKET SNAPSHOT & GROWTH ENGINE

13.2. MARKET OVERVIEW

13.3. PAIN MANAGEMENT

13.3.1. MARKET OVERVIEW

13.3.2. MARKET SIZE & FORECAST

13.4. HORMONE REPLACEMENT THERAPY

13.4.1. MARKET OVERVIEW

13.4.2. MARKET SIZE & FORECAST

13.5. ANTI-AGING & SKIN CARE

13.5.1. MARKET OVERVIEW

13.5.2. MARKET SIZE & FORECAST

13.6. NUTRITIONAL SUPPLEMENTS

13.6.1. MARKET OVERVIEW

13.6.2. MARKET SIZE & FORECAST

13.7. OTHERS

13.7.1. MARKET OVERVIEW

13.7.2. MARKET SIZE & FORECAST

14. AGE COHORT

14.1. MARKET SNAPSHOT & GROWTH ENGINE

14.2. MARKET OVERVIEW

14.3. ADULT

14.3.1. MARKET OVERVIEW

14.3.2. MARKET SIZE & FORECAST

14.4. GERIATRIC

14.4.1. MARKET OVERVIEW

14.4.2. MARKET SIZE & FORECAST

14.5. PEDIATRIC

14.5.1. MARKET OVERVIEW

14.5.2. MARKET SIZE & FORECAST

15. COMPETITIVE LANDSCAPE

15.1. COMPETITION OVERVIEW

15.2. MARKET SHARE ANALYSIS

15.2.1. AVELLA SPECIALTY PHARMACY

15.2.2. CAPS

15.2.3. FAGRON

15.2.4. FRESENIUS KABI

15.2.5. PENCOL PHARMACY

16. KEY COMPANY PROFILES

16.1. AVELLA SPECIALTY PHARMACY

16.1.1. BUSINESS OVERVIEW

16.1.2. PRODUCT OFFERINGS

16.1.3. KEY STRATEGIES

16.1.4. KEY STRENGTHS

16.1.5. KEY OPPORTUNITIES

16.2. CAPS

16.2.1. BUSINESS OVERVIEW

16.2.2. PRODUCT OFFERINGS

16.2.3. KEY STRATEGIES

16.2.4. KEY STRENGTHS

16.2.5. KEY OPPORTUNITIES

16.3. FAGRON

16.3.1. BUSINESS OVERVIEW

16.3.2. PRODUCT OFFERINGS

16.3.3. KEY STRATEGIES

16.3.4. KEY STRENGTHS

16.3.5. KEY OPPORTUNITIES

16.4. FRESENIUS KABI

16.4.1. BUSINESS OVERVIEW

16.4.2. PRODUCT OFFERINGS

16.4.3. KEY STRATEGIES

16.4.4. KEY STRENGTHS

16.4.5. KEY OPPORTUNITIES

16.5. PENCOL PHARMACY

16.5.1. BUSINESS OVERVIEW

16.5.2. PRODUCT OFFERINGS

16.5.3. KEY STRATEGIES

16.5.4. KEY STRENGTHS

16.5.5. KEY OPPORTUNITIES

17. OTHER PROMINENT VENDORS

17.1. AUSTIN COMPOUNDING PHARMACY

17.1.1. BUSINESS OVERVIEW

17.1.2. PRODUCT OFFERINGS

17.2. CAPSTONE COMPOUNDING PHARMACY

17.2.1. BUSINESS OVERVIEW

17.2.2. PRODUCT OFFERINGS

17.3. CHARLES RIVER LABORATORIES

17.3.1. BUSINESS OVERVIEW

17.3.2. PRODUCT OFFERINGS

17.4. DOUGHERTY'S PHARMACY

17.4.1. BUSINESS OVERVIEW

17.4.2. PRODUCT OFFERINGS

17.5. EASTERN STATES COMPOUNDING PHARMACY

17.5.1. BUSINESS OVERVIEW

17.5.2. PRODUCT OFFERINGS

17.6. EVERWELL SPECIALTY PHARMACY

17.6.1. BUSINESS OVERVIEW

17.6.2. PRODUCT OFFERINGS

17.7. HARROW

17.7.1. BUSINESS OVERVIEW

17.7.2. PRODUCT OFFERINGS

17.8. HILL’S COMPOUNDING PHARMACY AND MILFORD PHARMACY

17.8.1. BUSINESS OVERVIEW

17.8.2. PRODUCT OFFERINGS

17.9. INNOVATIVE RX

17.9.1. BUSINESS OVERVIEW

17.9.2. PRODUCT OFFERINGS

17.10. INSTITUTIONAL PHARMACY SOLUTIONS

17.10.1. BUSINESS OVERVIEW

17.10.2. PRODUCT OFFERINGS

17.11. ITC COMPOUNDING PHARMACY

17.11.1. BUSINESS OVERVIEW

17.11.2. PRODUCT OFFERINGS

17.12. MCGUFF COMPANY

17.12.1. BUSINESS OVERVIEW

17.12.2. PRODUCT OFFERINGS

17.13. MEDIVERA COMPOUNDING PHARMACY

17.13.1. BUSINESS OVERVIEW

17.13.2. PRODUCT OFFERINGS

17.14. NEPHRON PHARMACEUTICALS

17.14.1. BUSINESS OVERVIEW

17.14.2. PRODUCT OFFERINGS

17.15. PCCA

17.15.1. BUSINESS OVERVIEW

17.15.2. PRODUCT OFFERINGS

17.16. PRECISION COMPOUNDING PHARMACY

17.16.1. BUSINESS OVERVIEW

17.16.2. PRODUCT OFFERINGS

17.17. QUVA PHARMA

17.17.1. BUSINESS OVERVIEW

17.17.2. PRODUCT OFFERINGS

17.18. SIXTH AVENUE MEDICAL PHARMACY

17.18.1. BUSINESS OVERVIEW

17.18.2. PRODUCT OFFERINGS

17.19. ST. ANTHONY PHARMACY

17.19.1. BUSINESS OVERVIEW

17.19.2. PRODUCT OFFERINGS

17.20. THE COMPOUNDING PHARMACY OF AMERICA

17.20.1. BUSINESS OVERVIEW

17.20.2. PRODUCT OFFERINGS

17.21. TRIANGLE COMPOUNDING

17.21.1. BUSINESS OVERVIEW

17.21.2. PRODUCT OFFERINGS

17.22. VALOR COMPOUNDING PHARMACY

17.22.1. BUSINESS OVERVIEW

17.22.2. PRODUCT OFFERINGS

17.23. VERTISIS CUSTOM PHARMACY

17.23.1. BUSINESS OVERVIEW

17.23.2. PRODUCT OFFERINGS

18. REPORT SUMMARY

18.1. KEY TAKEAWAYS

18.2. STRATEGIC RECOMMENDATIONS

19. QUANTITATIVE SUMMARY

19.1. MARKET BY PRODUCT TYPE

19.2. MARKET BY PHARMACY TYPE

19.3. MARKET BY STERILITY TYPE

19.4. MARKET BY COMPOUNDING TYPE

19.5. MARKET BY APPLICATION

19.6. MARKET BY AGE COHORT

20. APPENDIX

20.1. RESEARCH METHODOLOGY

20.2. RESEARCH PROCESS

20.3. REPORT ASSUMPTIONS & CAVEATS

20.3.1. KEY CAVEATS

20.3.2. CURRENCY CONVERSION

20.4. ABBREVIATIONS

Select a license type that suits your business needs

Single User Licence

$4200.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email

5 User Licence

$4999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Corporate Licence

$5999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Datasheet Licence

$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Frequently Asked Questions

How big is the U.S. compounding pharmacies market?

The U.S. compounding pharmacies market size was valued at USD 4.89 billion in 2023 and is expected to reach USD 6.21 billion by 2029.

What is the growth rate of the U.S. compounding pharmacies market?

The U.S. compounding pharmacies market is expected to grow at a CAGR of 4.06% from 2023 to 2029.

What are the significant trends in the U.S. compounding pharmacies market?

Advanced technology integration, growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women, and growing collaboration between compounding pharmacies & healthcare providers are significant trends in the U.S. compounding pharmacies industry.

Which compounding type segment dominates the U.S. compounding pharmacies market share?

The pharmaceutical ingredient alteration (PIA) compounding type held the largest U.S. compounding pharmacies market share, accounting for over 39% in 2023.

Who are the key players in the U.S. compounding pharmacies market?

Avella Specialty Pharmacy, CAPS, Fagron, Fresenius Kabi, and PenCol Pharmacy are the key players in the U.S. compounding pharmacies market.